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Figure S1. Plk4 inhibition by centrinone in the two-cell embryo prevents bipolar spindle formation. (A) Two-cell embryos injected with mRNA codifying 
EGFP-EB3 (black, inverted). Embryos were imaged for 10–16 h until spindle assembly occurred in standard untreated conditions (control, top), in the 
presence of 2 µM centrinone (middle), and in the presence of 1 µM Aurora A inhibitor 1 (bottom). Inhibition of Plk4 by the addition of centrinone affects 
spindle assembly, which is severely impaired compared with both control and Aurora A inhibition. However, the latter treatment leads to formation of a 
smaller spindle compared with controls. (B) Mitotic spindle length at metaphase in two-cell embryos. The quantification was performed for controls (n = 
16), after Plk4 kinase inhibition (centrinone, n = 19), and after Aurora A inhibition (AurA Inh 1, n = 12). Error bars indicate SD of the mean. Differences 
between each individual inhibitor and control conditions are statically significant (***, P < 0.0001).
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Figure S2. Plk4 and Aurora A facilitate microtubule nucleation upon meiotic resumption. (A–C) Time-lapse series of oocytes injected with EGFP-EB3 
(black, inverted) and histone H2B-mRFP (red) mRNAs. Progression through early stages of meiosis I was imaged in untreated control conditions (A) or in 
the presence of 2 µM centrinone (B) and Aurora A inhibitor 1 (AurA Inh1; C). (D) To assess reversion of the Aurora A inhibition phenotype caused by 
Aurora A inhibitor 1, oocytes were coinjected with mRNA to express AurA Kinase G229L. Time (in hours :minutes) relative to NEBD. (E) Quantification of 
the size of the projected spindle area. Plk4 inhibition by centrinone at 2 µM (n = 23). Centrinone significantly reduces the kinetics of microtubule growth, 
as determined by the size of the spindle area, compared with controls (n = 44). Error bars indicate SEM. P-values are shown in Table S1. See also Videos 
1 and 2 and Figs. 1 and 2. (F) Quantification of the size of the projected spindle area throughout time after Aurora A inhibition with Aurora A inhibitor 
1 (n = 10). Defects caused by Aurora A inhibitor 1 treatment are significantly rescued by coexpression of Aurora A kinase G229L (n = 17). Error bars 
indicate SEM. P-values are shown in Table S1.
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Figure S3. Plk4 and Aurora A facilitate microtubule nucleation upon meiotic resumption. (A–C) Immunostaining of oocytes at prometaphase (120 min after 
NEBD) to reveal α-tubulin (green, top; inverted, bottom) and DNA (blue, top). Depicted are oocytes that underwent meiosis in control conditions (A), in the 
presence of Aurora A inhibitor 1 (B), and treated with the Plk4 inhibitor centrinone (C). (D) Quantification of spindle area of oocytes fixed and stained for 
α-tubulin. Inhibition of Plk4 and Aurora A reduces the area of the spindle significantly. Error bars represent SD of the mean (***, P < 0.001). Bars, 5 µm.
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Figure S4. VX-680–mediated inhibition of Plk4 and Aurora A diminishes microtubule nucleation. Dose–response of oocytes to increased concentrations 
of VX-680. (A–C) Time-lapse series of oocytes injected with mRNA encoding EGFP-EB3 (green, top; inverted, bottom) and H2B-mRFP (red, top). Meiosis I 
was imaged in untreated control conditions (A) and in oocytes treated with 0.5 µM V-680 (B; n = 11), 1 µM VX-680 (C; n = 27), and 5 µM VX-680 (D; 
n = 11). (E) Size of the projected spindle area plotted over time, quantified in oocytes undergoing meiosis I in the conditions in A–D. Error bars indicate 
SEM. For p-values, see Table S1. (F–I) Time-lapse series of oocytes injected with EGFP-EB3 (green, top; inverted, bottom) and H2B-mRFP (red, top) mRNAs. 
Meiosis I was imaged in untreated control conditions (F) and in the presence of 1 μM of the Src kinase inhibitor saracatinib (G). (H and I) Time-lapse series 
of oocytes expressing EGF PEB3 (green, top; inverted, bottom) and H2B-mRFP (red, top) mRNA undergoing meiosis I in the presence of VX-680. Treatment 
with VX-680 (H) induces exit of meiosis I (7:30) and polar body extrusion failure, followed by the assembly of a meiosis II spindle (14:00). Expression of 
Aurora B G165L (I) is able to rescue polar body extrusion defects, and a meiosis I spindle remains until 14:00. Time (in hours :minutes) relative to NEBD. 
(J and K) Size of the projected spindle area measured throughout time. (J) Inhibition of Src tyrosine kinases (n = 12) has no effect on microtubule growth 
compared with controls (n = 44). Error bars indicate SEM. (K) Treatment of oocytes with 1 μM VX-680 (n = 26) significantly reduces the spindle area 
compared with controls (n = 44) but does not significantly differ in oocytes expressing Aurora B G165L (n = 9). Error bars represent SEM. (L) Percentage 
of oocytes that are delayed in meiosis I (MI) or exit meiosis I during 20 h of imaging, when followed in the presence of VX-680 with or without expression 
of Aurora B G165L. VX-680 treatment (n = 60) causes 80% of the oocytes to exit meiosis I with polar body extrusion failure (see H), which is reduced to 
15% in oocytes expressing Aurora B G165L (n = 20). (M) Mean time spent in meiosis I in the presence of VX-680 is significantly prolonged as a result of 
Aurora B G165L expression (***, P < 0.001). Error bars indicate SD of mean.
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Figure S5. Plk4 phosphorylates Aurora A on five phosphosites in vitro. (A) Purified recombinant WT or G95R human PLK4 (amino acids 1–284) or 
WT or G216L (equivalent to murine G229L) full-length human Aurora A was assayed by quantified mobility shift using EZ Reader technology with the 
appropriate Aurora A or PLK4 fluorescent peptide substrate in the presence of DMSO (control) or VX-680 (10 M), in the presence of 1 mM ATP (final 
concentration), to mimic cellular ATP levels. (B) Purified recombinant WT PLK4 was incubated with D274N Aurora A (+/− 1 mM Mg-ATP) for 2 h at 37°C 
before in-solution digestion and analysis by LC-MS/MS. PLK4 phosphorylates Aurora A on five sites (S54, S245, T287/T288, T292, and T347), which 
are highlighted in red (top). Peptide sequence with associated m/z values are depicted with Mascot scores and phosphosite confidence (bottom). There 
was no phosphorylation of D274N Aurora A in the absence of PLK4 (1–284) or if D274N Aurora A was incubated with 1 mM Mg-ATP. (C) Purified human 
kinase-dead Aurora A (D274N) was incubated alone and in the presence of WT or kinase-dead (D154A) PLK4 (1–284), or in the presence of 10 mM 
centrinone with 1 mM Mg-ATP. Reactions were analyzed at the indicated time-points by Western blotting using the same phosphospecific antibody used 
for oocyte pT288 analysis. (D) l-phosphatase–treated WT Aurora A (which has very low-level basal activity caused by the enzymatic dephosphorylation of 
T288 but can be “reactivated” by activating factors) was incubated with the indicated purified proteins for 30 min at 37°C in the presence of Mg-ATP, and 
Aurora A activity was then assayed by the inclusion of a fluorescent Aurora A substrate peptide derived from the consensus kemptide sequence. Activity 
was analyzed in kinetic mode for 30 cycles and converted to total peptide phosphorylation. (E) WT Aurora A, which is highly active after expression in 
bacteria, was assayed for hyperactivation as in D in the presence or absence of WT PLK4 (1–284). Control kinetic reactions containing either peptide or 
PLK4 (1–284) alone exhibited no kemptide phosphorylation. Data are presented as the mean ± SD for duplicate reactions, with similar results seen in at 
least one independent experiment. (F–K) MS2 spectra generated by HCD or EThcD of tryptic phosphopeptides derived from human kinase-dead (D274N) 
Aurora A phosphorylated by PLK4 (1–285). The peptide sequence and the identified phosphosite is detailed on each mass spectrum. (F) Doubly charged 
ion at m/z 614.2, generated by HCD, identifying pS54; (G) triply charged ion at m/z 665.0, generated by EThcD, providing additional evidence for 
pS54; (H) doubly charged ion at m/z 847.9, generated by HCD, identifying pT347; (I) triply charged ion at m/z 708.3, generated by HCD, identifying 
pS245; (J) doubly charged ion at m/z 1,073.5, generated by HCD identifying pT292; and (K) doubly charged ion at m/z 1,074.0, generated by HCD, 
identifying the activating T-loop residue pT287 or pT288. The presence of pT288 on Aurora A after incubation with PLK4 was confirmed by Western 
blotting using a pT288 phosphospecific antibody.
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Video 1. Plk4 is required for acentriolar spindle assembly. Oocytes expressing EGFP-EB3 (green, right; inverted black, left) 
and histone H2B-mRFP (red, right). Progression through the early stages of meiosis was imaged under the indicated conditions. 
Treatment with centrinone or coexpression of Plk4Δkinase significantly delays microtubule growth. Inhibition of Plk4 with 5 µM 
centrinone can be partially rescued by expression of a drug-resistant Plk4 allele (G95R). Z stacks are composed of 20 optical 
sections every 3 µm. Images were acquired every 15 min. NEBD corresponds to time 00:00 (hours :minutes). See also Fig. 1 (A–E).
Video 2. Aurora A plays a role in acentriolar spindle assembly. Oocytes injected with mRNA encoding for EGFP-EB3 (gray, 
right; inverted black, left) and histone H2B-mRFP (red, right) to follow the dynamics of microtubule nucleation and spindle 
assembly. Progression through the early stages of meiotic maturation is shown. Imaging was performed in conditions as 
indicated (untreated control, treatment with 1 µM Aurora A inhibitor 1). Compared with controls, inhibition of Plk4 causes a 
significant delay in the initiation of microtubule growth that can be rescued by expression of a drug-resistant Aurora A G229L. 
Z stacks are composed of 20 optical sections 3 µm apart. Images were acquired every 15 min. NEBD corresponds to time 
00:00 (hours :minutes). See also Fig. 2 (A and B) and Fig. S2.
Video 3. Aurora A predominates over Plk4 to initiate microtubule nucleation. Time-lapse imaging of oocytes injected with 
mRNA encoding EGFP-EB3 (green, right; inverted black, left), and histone H2B-mRFP (red, right panels). Shown is progression 
through the early stages of meiosis under the indicated conditions. Treatment with VX-680 significantly delays microtubule 
growth, and these defects can be restored by expression of drug-resistant alleles of Aurora A (G229L) and Plk4 (G95R). Z 
stacks are composed of 20 optical sections every 3 µm. Images were acquired every 15 min. NEBD corresponds to time 
00:00 (hours :minutes). See also Figs. 5 and S4.
Video  4. Ran has distinct functions from Aurora A and Plk4 during spindle assembly of meiosis I.  Time-lapse imaging of 
oocytes injected with mRNAs for EGFP-EB3 (inverted, black) and histone H2B-mRFP (control), dominant-negative Ran (T24N), 
or constitutively active Ran (Q69L). Progression through meiosis I was followed either in untreated conditions (control) or in the 
presence of Aurora A inhibitor 1 or centrinone. Expression of RanT24N further reduces microtubule nucleation. RanQ69L is not 
able to rescue the initial delay of microtubule nucleation caused by inhibition of Aurora A and Plk4; however, it is able to increase 
the amount of nucleated microtubules at later stages of meiosis progression. Z stacks are composed of 20 optical sections every 
3 µm. Images were acquired every 15 min. NEBD corresponds to time 00:00 (hours :minutes). See also Fig. 7.
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Table S1. P-values for size of projected spindle area
 Condition  15 min  30 min  45 min  60 min  75 min  90 min  115 min  120 min 
Control versus  
1 µM AurA Inh 1
6.4 × 10−10 9.5525 × 10−11 9.557 × 10−11 9.557 × 10−11 9.557 × 10−11 9.5525 × 10−11 9.557 × 10−11 9.557 × 10−11
Control versus  
2 µM AurA Inh 1 
0.00055725 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832
Control versus  
5 µM AurA Inh 1
1.2339 × 10−6 3.7412 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7
Control versus AurA 
Inh 1 + centrinone
3.0624 × 10−6 0.000001019 0.000001019 0.000001019 0.000001019 0.000001019 0.000001019 0.000001019
Control versus AurA 
Inh 1 + RanT24N
2.6688 × 10−7 6.9596 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8
Control versus AurA 
Inh 1 + RanQ69L
6.9716 × 10−7 4.6063 × 10−7 2.4454 × 10−7 1.591 × 10−7 1.974 × 10−7 1.7725 × 10−7 1.4275 × 10−7 1.4275 × 10−7
Control versus 
BI2536
0.012183 0.000051798 1.3604 × 10−6 1.9255 × 10−6 9.5662 × 10−7 3.2343 × 10−7 1.3948 × 10−7 9.5251 × 10−8
Control versus  
2 µM centrinone
5.1942 × 10−10 9.3422 × 10−11 8.5589 × 10−11 8.5589 × 10−11 2.6366 × 10−10 2.2217 × 10−10 7.84 × 10−11 9.3422 × 10−11
Control versus 
centrinone + 
RanQ69L
6.8605 × 10−6 7.2544 × 10−7 2.1875 × 10−7 1.975 × 10−7 1.975 × 10−7 1.6083 × 10−7 8.6115 × 10−8 1.062 × 10−7
Control versus 
centrinone + 
RanT24N
6.9716 × 10−7 2.1975 × 10−7 1.4275 × 10−7 1.4275 × 10−7 1.4275 × 10−7 1.4275 × 10−7 1.4275 × 10−7 1.4275 × 10−7
Control versus  
5 µM centrinone
3.6307 × 10−11 4.08 × 10−12 4.08 × 10−12 3.7436 × 10−12 4.4459 × 10−12 3.7436 × 10−12 3.7436 × 10−12 4.08 × 10−12
Control versus 
Plk4Dkinase
5.4012 × 10−7 7.7505 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8 5.6386 × 10−8
Control versus 
MLN8237
0.00055725 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832 0.00029832
Control versus 
RanQ69L
0.063347 0.72869 0.19393 0.22344 0.052579 0.017939 0.0041921 0.0063853
Control versus 
RanT24N
4.1174 × 10−7 8.3458 × 10−9 1.1505 × 10−9 9.4751 × 10−9 1.0442 × 10−9 8.5956 × 10−10 8.5956 × 10−10 8.5956 × 10−10
Control versus 
saracatinib
0.067683 0.006039 0.017969 0.19776 0.4661 0.61062 0.74179 0.4661
Control versus  
1 µM VX680
1.9423 × 10−11 2.0671 × 10−12 2.0671 × 10−12 2.068 × 10−12 2.068 × 10−12 2.068 × 10−12 2.0671 × 10−12 2.068 × 10−12
Control versus 
0.5 µM VX680
1.3716 × 10−6 3.7412 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7
Control versus 5 µM 
VX680
1.2339 × 10−6 3.7412 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7 3.7431 × 10−7
Control versus VX680 
+ AurBG165L
7.9863 × 10−6 2.8848 × 10−6 2.8862 × 10−6 2.8862 × 10−6 2.8862 × 10−6 2.8862 × 10−6 2.8862 × 10−6 2.8862 × 10−6
VX680 versus 
VX680 G95R
0.3758 0.0016 0.0019 0.0131 0.0766 0.3183 0.5196 0.1868
VX680 versus 
VX680 G229L
3.54 × 10−6 0.0001 0.0001 0.0006 8.20 × 10−6 1.85 × 10−7 6.13 × 10−8 6.13 × 10−8
VX680 versus 
VX680 G229L 
G95R
5.89 × 10−5 0.00043517 9.14 × 10−6 1.32 × 10−7 1.14 × 10−7 1.14 × 10−7 2.02 × 10−7 1.52 × 10−7
VX680 versus 
VX680 G229LKD
0.375871202 0.001605856 0.001998491 0.013187402 0.076647698 0.318325298 0.519675896 0.186898398
VX680 versus 
VX680 G229L 
versus VX680 
G229L G95R
3.54 × 10−6 0.000140738 0.000199965 0.000662382 8.20 × 10−6 1.85 × 10−7 6.13 × 10−8 6.13 × 10−8
5 µM centrinone 
versus 5 µM 
centrinone + G95R
5.89 × 10−5 0.00043517 9.14 × 10−6 1.32 × 10−7 1.14 × 10−7 1.14 × 10−7 2.02 × 10−7 1.52 × 10−7
AurA Inh 1 versus 
AurA Inh 1 + 
RanT24N
0.606773474 0.047058898 0.017578487 0.000300665 9.69 × 10−5 0.000129373 7.21 × 10−5 0.000112097
AurA Inh 1 versus 
AurA Inh 1 + 
RanQ69L
0.203186877 0.231006538 0.049441661 0.149633765 0.238454775 0.238415544 0.045264604 0.01578488
Centrinone versus 
centrinone + 
RanT24N
0.74128827 0.169839443 0.005148887 0.001660344 0.001660344 0.001868721 0.009624001 0.012962541
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 Condition  15 min  30 min  45 min  60 min  75 min  90 min  115 min  120 min 
Centrinone versus 
centrinone + 
RanQ69L
0.04453514 0.323132062 0.668540789 0.553298127 0.668540789 0.391830149 0.121638544 0.075325766
AurA Inh 1 versus 
AurA Inh 1 + 
Aurora A G229L
0.9949 0.10510 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Control versus AurA 
Inh 1 + Aurora A 
G229L
0.85170 0.01350 0.42900 0.0137 0.0001 0.0001 0.0001 0.0001
AurA Inh 1, Aurora A inhibitor 1.
Table S2. Values of t50 and slope together with their relative confidence intervals of the four parameters logistic function fitted on the spindle  
area quantifications
 Experimental conditions  t50  95% confidence interval t50  Slope  95% confidence interval slope 
Control (n = 44) 38.658 30.995 46.321 0.020352 0.013328 0.027376
1 µM AurA Inh 1 (n = 21) 55.008 52.286 57.731 0.032656 0.026754 0.038559
2 µM AurA Inh 1 (n = 5) 74.533 72.889 76.177 0.032978 0.02933 0.036627
5 µM AurA Inh 1(n = 6) 86.767 73.849 99.686 0.022378 0.0080442 0.036712
AurA Inh 1 + centrinone (n = 10) 72.486 69.974 74.999 0.028825 0.024541 0.033109
AurA Inh 1 + RanT24N (n = 13) 67.998 64.954 71.042 0.024239 0.020526 0.027951
AurA Inh 1 + RanQ69L (n = 12) 56.429 50.999 61.86 0.023622 0.017333 0.029911
BI2536 (n = 15) 41.12 33.943 48.298 0.020018 0.013683 0.026354
2 µM centrinone (n = 23) 55.425 51.87 58.98 0.028567 0.022641 0.034492
Centrinone + RanQ69L (n = 13) 57.816 54.195 61.437 0.022653 0.018776 0.02653
Centrinone + RanT24N (n = 12) 68.56 66.378 70.742 0.026378 0.023252 0.029503
5 µM centrinone (n = 26) 66.966 63.872 70.06 0.028869 0.0236 0.034139
Centrinone + Plk4G95R (n = 25) 47.913 43.63 52.196 0.022972 0.018217 0.027727
Plk4Δkinase (n = 13) 73.431 70.088 76.774 0.023294 0.019477 0.027112
MLN8237 (n = 10) 72.77 71.343 74.198 0.031551 0.028649 0.034453
RanQ69L (n = 22) 42.447 35.434 49.459 0.021722 0.014597 0.028847
RanT24N (n = 18) 61.174 56.454 65.895 0.019169 0.015426 0.022912
Saracatinib (n = 12) 45.521 41.265 49.778 0.022371 0.017847 0.026895
1 µM VX-680 (n = 26) 77.784 76.482 79.086 0.034691 0.031493 0.03789
0.5 µM VX-680 (n = 11) 84.009 79.265 88.753 0.025077 0.018689 0.031465
5 µM VX-680 (n = 11) 86.767 73.849 99.686 0.022378 0.0080442 0.036712
VX-680 + AurBG165L (n = 9) 76.275 71.776 80.775 0.023603 0.018307 0.028899
VX-680 + AurAG229L (n = 15) 62.845 60.241 65.448 0.027088 0.023176 0.031001
VX-680 + AurAG229LKD (n = 8) 92.308 88.018 96.599 0.032611 0.022939 0.042284
VX-680 + AurAG229L + Plk4G95R (n = 14) 47.862 45.932 49.792 0.02801 0.024898 0.031122
VX-680 + Plk4G95R (n = 10) 66.39 62.393 70.387 0.022694 0.018389 0.026999
AurA Inh 1 + AurAG229L (n = 17) 26.97 21.86 33.5 0.02929 0.01985 0.04647
Global kinetics was monitored over a 120-min time window. Fitting is based on all available independent measurements (n). AurA Inh 1, Aurora A inhibitor 1.
Table S3. Inhibitor concentrations
 Compound  Concentration  Remarks 
BI2536 100 nM Concentration maximally reduces phosphorylation of BubR1 at T669 in mouse oocytes (Solc et al., 2015); and 
abolishes Plk1 kinase activity in vitro (Scutt et al., 2009)
MLN8237 500 nM Efficiently prevents Aurora A activation and activity in vivo (Hochegger et al., 2013)
Aurora A inhibitor 1 1–5 µM Concentration suppresses mitotic Aurora A autophosphorylation on Thr288 in vitro (Yuan et al., 2012)
Aurora A inhibitor 1 Dose–response Increasing concentrations above 1 µM to 2 µM or 5 µM does not significantly further affect microtubule growth (not 
depicted)
Centrinone 2–5 µM 1–10 µM inhibits centriole assembly in Xenopus embryos (Wong et al., 2015); 5 µM phenocopies effect of 
Plk4ΔKinase in the mouse oocyte (Fig. 1; compare Fig. S1); treatment of 2-cell embryos with 2 µM phenocopies 
Plk4dsRNAi (Fig. S1; compare Coelho et al., 2013); phenotype induced by 5 µM centrinone is reversible by 
expression of Plk4 G95R (Fig. 1, C and E)
VX-680 0.5–5 µM 1 µM abolishes Aurora A kinase activity in vitro but not that of inhibitor-resistant (G216L) Aurora A (Scutt et al., 2009)
VX-680 Dose–response (Fig. S4) Phenotype caused by treatment with VX-680 at 1 µM concentration is reversible by expression of inhibitor-resistant 
(G216L equivalent) Aurora A (Fig. 5)
Saracatinib 1 µM Used at 1 µM to inhibit Src kinases in vivo (Liu et al., 2011)
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Table S4. FRAP values for t1/2, mobile fraction, and their relative confidence intervals
Condition  t1/2  95% confidence interval t1/2  Mobile fraction  95% confidence mobile fraction 
 Cytoplasmic MTOCs, stage 1 
Control (n = 10) 2.193 2.085 2.306 0.6092 0.6028 0.6158
Centrinone (n = 12) 2.988 2.887 3.092 0.6616 0.6556 0.6678
AurA Inh 1 (n = 10) 2.300 2.045 2.582 0.5010 0.4886 0.5142
RAN (n = 10) 1.938 1.842 2.038 0.6349 0.6284 0.6415
 Cytoplasmic MTOCs, stage 2 
Control (n = 14) 1.930 1.813 2.053 0.5827 0.5752 0.5903
Centrinone (n = 15) 2.414 2.338 2.493 0.6526 0.6478 0.6576
AurA Inh 1 (n = 15) 2.267 2.120 2.422 0.6375 0.6284 0.6469
RAN (n = 14) 3.700 3.492 3.922 0.6464 0.6348 0.6586
 Cytoplasmic MTOCs, stage 3 
Control (n = 14) 2.221 2.106 2.341 0.6482 0.6409 0.6558
Centrinone (n = 13) 2.431 2.350 2.514 0.6390 0.6341 0.6440
AurA Inh 1 (n = 9) 2.275 2.155 2.400 0.6030 0.5960 0.6103
RAN (n = 9) 2.761 2.626 2.901 0.6327 0.6249 0.6409
 MTOCs at chromosomes, stage 1 
Control (n = 7) 1.745 1.621 1.875 0.6371 0.6286 0.6458
Centrinone (n = 13) 2.397 2.270 2.529 0.6141 0.6065 0.6219
AurA Inh 1 (n = 19) 2.666 2.474 2.870 0.6080 0.5968 0.6198
RAN (n = 12) 2.849 2.695 3.012 0.6455 0.6365 0.6549
 MTOCs at chromosomes, stage 2 
Control (n = 10) 2.165 2.049 2.286 0.4968 0.4912 0.5026
Centrinone (n = 12) 2.397 2.227 2.578 0.6556 0.6450 0.6666
AurA Inh 1 (n = 10) 2.732 2.500 2.983 0.5706 0.5583 0.5836
RAN (n = 10) 3.253 3.081 3.436 0.6580 0.6685 0.6810
 MTOCs at chromosomes, stage 3 
Control (n = 10) 1.896 1.763 2.036 0.5693 0.5609 0.5778
Centrinone (n = 12) 2.528 2.377 2.686 0.6660 0.6567 0.6757
AurA Inh 1 (n = 10) 2.078 1.915 2.250 0.6129 0.6026 0.6235
RAN (n = 10) 3.076 2.842 3.329 0.5749 0.5626 0.5879
AurA Inh 1, Aurora A inhibitor 1.
Table S5. Sequences of oligonucleotides
 Oligonucleotide  Sequence (5′ to 3′) 
RanQ69L_Fwd  AGT TCA ATG TAT GGG ACA CAG CCG GCC TGG AGA AAT TCG GTG GAC TGA GAG ATGG 
RanQ69L_Rev  CCA TCT CTC AGT CCA CCG AAT TTC TCC AGG CCG GCT GTG TCC CAT ACA TTG AACT 
AurAG229L_Fwd  CTG ATT CTA GAA TAT GCG CCC CTT CTA ACA GTC TAT AGA GAG CTCC 
AurAG229L_Rev  GGA GCT CTC TAT AGA CTG TTA GAA GGG GCG CAT ATT CTA GAA TCAG 
Plk4G95R_Fwd  CTG GTA TTA GAA ATG TGC CAT AAT AGA GAA ATG AAC AGG TAT CTA AAG AAT AG 
Plk4G95R_Rev  CTA TTC TTT AGA TAC CTG TTC ATT TCT CTA TTA TGG CAC ATT TCT AAT ACC AG 
AurBG165L_Fwd  CCT GGA ATA CGC CCC TCG CCT GGA ACT CTA CAA GGA ACTG 
AurBG165L_Rev  CAG TTC CTT GTA GAG TTC CAG GCG AGG GGC GTA TTC CAGG 
AurAK175R_Fwd  GCA AGT TCA TCC TGG CTC TGA GGG TGC TGT TTA AAA CAC AGC TGG 
AurAK175R_Rev  CCA GCT GTG TTT TAA ACA GCA CCC TCA GAG CCA GGA TGA ACT TGC 
Fwd, forward; Rev, reverse.
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